Drug Trial Radar · NCT07780565
Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Aug 30, 2029
Study completion Aug 30, 2031
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Carna Biosciences, Inc.
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to find the recommended dose of monzosertib in patients with relapsed/refractory AML and high-risk MDS. The safety and effects of monzosertib will also be studied.
Conditions
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome
Interventions
MonzosertibDrug
Give by mouth
PosaconazoleDrug
Given by mouth
IsavuconazoleDrug
Given by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Adverse Events (AEs).Time frame: Through study completion; an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UT MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.